Understanding the GLP-1 Phenomenon
First, let's quickly recap what these medications are. GLP-1 receptor agonists, sold under brand names like Ozempic, Wegovy, and Mounjaro, are injectable drugs that mimic a natural gut hormone. This hormone, called glucagon-like peptide-1, sends signals
to your brain that you are full, slows down how quickly your stomach empties, and helps regulate blood sugar. Their effectiveness in promoting significant weight loss and improving glycaemic control has made them a breakthrough in treating both obesity and type 2 diabetes. However, their use has raised a billion-dollar question: are the benefits permanent, or do they only last as long as the treatment?
The November 2026 Study's Core Findings
A highly anticipated observational study published in 'The Lancet Regional Health Europe' on November 9, 2026, sheds new light on this very issue, focusing specifically on patients with type 2 diabetes. Researchers analysed data from over 80,000 patients who had started on a GLP-1 medication. The study compared those who continued the therapy against those who discontinued it. The results were stark: patients who stopped taking the medication had approximately double the risk of suffering a heart attack, stroke, or death from any cause compared to those who remained on the treatment. The rate of these major adverse events was 3.94 per 100 person-years in the group that stopped, versus 1.96 in the group that continued.
The Inevitable Weight Regain
While the November 2026 study focused on cardiovascular risk in diabetics, its findings align with a large body of evidence on weight regain. Multiple studies confirm that when you stop taking GLP-1 drugs, the lost weight typically returns. A 2022 clinical trial showed that patients regained two-thirds of the weight they lost within a year of discontinuing the medication. This happens because the medication's effects on appetite and fullness fade once it clears from your system, which can take several weeks. Your natural hunger cues return, and the 'food noise'—the constant thoughts about eating that the drug silenced—often comes back. This is not a failure of willpower but a predictable biological response as the body's hormones revert to their pre-treatment state.
Beyond Weight: Metabolic Repercussions
The consequences of stopping extend beyond the number on the scale. For people with or at risk of type 2 diabetes, blood sugar control often worsens. Other cardiometabolic benefits gained during treatment—such as lower blood pressure and improved cholesterol levels—also tend to reverse, returning to baseline levels within about a year to 18 months. The new study suggests these reversals in traditional risk factors alone might not fully explain the increased cardiovascular risk, pointing to a more direct protective effect of the medication that is lost upon cessation. Essentially, obesity and diabetes are chronic conditions, and these drugs act as a management tool, not a one-time cure.
Why Do People Stop Taking GLP-1s?
Given the benefits, why do so many people stop? Real-world data from 2025 and 2026 point to several key reasons. High cost and lack of insurance coverage are the most common barriers, cited by over a third of patients. Persistent side effects, most often gastrointestinal issues like nausea and diarrhoea, are another major factor, causing about a third of discontinuations. Others stop because they have reached their weight loss goal, believing the treatment is complete, or due to medication shortages. Studies show discontinuation is common, with some reports finding that more than half of users stop within the first year.
















